

type of report	<b>Current report</b>
number	1/2015
Company	PHARMENA

**Information on the progress of clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA**

With reference to the Company's Strategy for 2012-2015 (published in current report No. 16/2012 of 13<sup>th</sup> April 2012) and the communication on the course of clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA (published in current report No. 56/2014 of 6<sup>th</sup> November 2014), the Management Board of PHARMENA S.A. informs that on 19<sup>th</sup> December 2014 there were 29 patients enrolled into phase II clinical trial of the 1-MNA anti-atherosclerosis medicinal product, including 10 patients who completed the trial.

The aim of phase II clinical trial of the 1-MNA anti-atherosclerosis medicinal product is to determine the effective dose of the drug and to confirm the lack of adverse effects in human organism, as far as tested doses of the drug are concerned. The Montreal Heart Institute is the entity supervising the clinical trial.

The Montreal Heart Institute remains to be the leading research and scientific centre in Canada, which specializes in cardiology, and it is one of the biggest institutes of this kind in the world. It is a globally renowned centre, which has introduced a multitude of innovative solutions, both on the international and the national scale. More information can be found on the Internet site: [www.icm-mhi.org](http://www.icm-mhi.org).

II phase clinical trials ("Proof of Concept") are financed from funds obtained from issuing Series D shares.

The information is made public due to the fact that realisation of phase II clinical trials is essential in order to commercialise the project concerning 1-MNA anti-atherosclerosis medicinal product, whereas possible revenue related with the commercialization of the drug may pose a significant influence on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board